Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Oncogene ; 35(21): 2777-88, 2016 05.
Article in English | MEDLINE | ID: mdl-26387546

ABSTRACT

The spinophilin (Spn, PPP1R9B) gene is located at 17q21.33, a region frequently associated with microsatellite instability and loss of heterozygosity, especially in breast tumors. Spn is a regulatory subunit of phosphatase1a (PP1), which targets the catalytic subunit to distinct subcellular locations. Spn downregulation reduces PPP1CA activity against the retinoblastoma protein, pRb, thereby maintaining higher levels of phosphorylated pRb. This effect contributes to an increase in the tumorigenic properties of cells in certain contexts. Here, we explored the mechanism of how Spn downregulation contributes to the malignant phenotype and poor prognosis in breast tumors and found an increase in the stemness phenotype. Analysis of human breast tumors showed that Spn mRNA and protein are reduced or lost in 15% of carcinomas, correlating with a worse prognosis, a more aggressive tumor phenotype and triple-negative tumors, whereas luminal tumors showed high Spn levels. Downregulation of Spn by shRNA increased the stemness properties along with the expression of stem-related genes (Sox2, KLF4, Nanog and OCT4), whereas ectopic overexpression of Spn cDNA reduced these properties. Breast tumor stem cells appeared to have low levels of Spn mRNA, and Spn loss correlated with increased stem-like cell appearance in breast tumors as indicated by an increase in CD44+/CD24- cells. A reduction of the levels of PPP1CA mimicked the cancer stem-like cell phenotype of Spn downregulation, suggesting that the mechanism of Spn involves PP1a. These increased cancer stem cell-like properties with reduced Spn might account for the malignant phenotype observed in Spn-loss tumors and may contribute to a worse patient prognosis.


Subject(s)
Breast Neoplasms/pathology , Microfilament Proteins/deficiency , Neoplastic Stem Cells/pathology , Nerve Tissue Proteins/deficiency , Animals , Breast Neoplasms/metabolism , Cell Line, Tumor , Cohort Studies , Female , Humans , Kruppel-Like Factor 4 , Microfilament Proteins/genetics , Microfilament Proteins/metabolism , Neoplastic Stem Cells/metabolism , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Prognosis
2.
Pathobiology ; 75(2): 85-94, 2008.
Article in English | MEDLINE | ID: mdl-18544963

ABSTRACT

Hereditary breast cancer arising in carriers of mutations in the BRCA1 and BRCA2 genes differs from sporadic breast cancer and from non-BRCA1/2 familial breast carcinomas. Most BRCA1 carcinomas have the basal-like phenotype and are high-grade, highly proliferating, estrogen receptor-negative and HER2-negative breast carcinomas, characterized by the expression of basal markers such as basal keratins, P-cadherin and epidermal growth factor receptor. BRCA1 carcinomas frequently carry p53 mutations. The basal-like phenotype is only occasionally found in BRCA2 carcinomas, which tend to be estrogen and progesterone receptor positive. BRCA1 and BRCA2 loss of heterozygosity is found in almost all BRCA1 and BRCA2 carcinomas, respectively. Both genotypes have a low frequency of HER2 expression/amplification. In addition, comparative genomic hybridization and array expression studies have revealed differences in chromosomal gains and losses as well as expression patterns between genotypes. Several studies have shown that hereditary carcinomas that are not attributable to BRCA1/2 mutations are heterogeneous and have phenotypic similarities to BRCA2 tumors. A small group of cases are secondary to mutations in other breast cancer susceptibility genes, such as p53, PTEN or CDH1. As a result of the low frequency of breast carcinomas attributable to mutations in these genes, it is very difficult to establish a specific phenotype for each genotype, other than the association of lobular carcinomas with CDH1 germline mutations. The pathological and molecular features of hereditary breast cancer can drive specific treatments and influence the process of mutation screening.


Subject(s)
Breast Neoplasms/genetics , Breast Neoplasms/pathology , Genetic Predisposition to Disease , BRCA1 Protein/genetics , BRCA2 Protein/genetics , Female , Humans , Mutation/genetics
6.
Life Sci ; 67(9): 1003-13, 2000.
Article in English | MEDLINE | ID: mdl-10954034

ABSTRACT

Autocrine expression of VEGF has been detected in endothelial cells under hypoxia or oxidative stress. However, the functional significance of this VEGF autocrine expression remains undefined. To analyze the role of autocrine VEGF in the endothelial response against injury, cultured bovine aorta endothelial cells (BAEC) were challenged with potentially cytotoxic substances with different chemical structure and pharmacologic properties, namely cytochalasin D (CyD), hydrogen peroxide (H2O2) and cyclosporine A (CsA). Our results revealed that: i. In particular conditions, exposure to potentially cytotoxic agents as CyD, H2O2 or CsA results in significant BAEC cytoprotection rather than injury. ii. The response to the 3 agents is shifted to a cell damaging pattern in the presence of a specific anti VEGF monoclonal antibody (mAb). iii. CyD and H2O2 markedly stimulate the autocrine expression of VEGF mRNA and VEGF protein. In conclusion, the present study reveals a protective mechanism of endothelial cells against injury involving autocrine VEGF production. Moreover, the occurrence of a significant increase in VEGF expression accompanying this defensive mechanism is further disclosed.


Subject(s)
Endothelial Growth Factors/physiology , Endothelium, Vascular/drug effects , Lymphokines/physiology , Amino Acid Sequence , Animals , Antibodies, Monoclonal/pharmacology , Antibody Specificity , Cattle , Cyclosporine/toxicity , Cytochalasin D/toxicity , Endothelial Growth Factors/biosynthesis , Endothelial Growth Factors/immunology , Endothelium, Vascular/metabolism , Endothelium, Vascular/physiology , Gene Expression Regulation/drug effects , Hydrogen Peroxide/toxicity , Immunosuppressive Agents/toxicity , Lymphokines/biosynthesis , Lymphokines/immunology , Molecular Sequence Data , Oxidants/toxicity , RNA, Messenger/biosynthesis , RNA, Messenger/metabolism , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
7.
Circ Res ; 85(12): 1132-8, 1999.
Article in English | MEDLINE | ID: mdl-10590239

ABSTRACT

The mechanisms involved in the blockade of proliferation in confluent endothelial cells are insufficiently understood. In this regard, the continuity of intercellular junctions appears to be critical to the regulation of endothelial monolayer cell growth. The present study examined the hypothesis that the disruption of the intercellular adherens junctions will trigger both endothelial cell proliferation and autocrine production of growth factors. With this purpose, we assessed the changes in growth, death resistance, and expression of vascular endothelial growth factor (VEGF) under conditions of disruption of the intercellular junctions between endothelial cells. Disruption of cell junctions was produced by means of a specific anti-vascular endothelial cadherin monoclonal antibody, EGTA, or cytochalasin D. Our results disclosed that these maneuvers induce an increase in VEGF mRNA production, with transcription of the 121-, 165-, and 189-amino acid isoforms of VEGF. Further evidence of the relationship between endothelial cells monolayer continuity and VEGF protein expression was obtained by the demonstration of an increase in VEGF protein, as determined by Western blot, induced by the aforementioned maneuvers, as well as by immunocytochemical detection of increased VEGF staining in the areas surrounding a mechanical endothelial injury and in endothelial cells at subconfluence. In functional terms, the autocrine expression of VEGF was associated with growth-promoting and cytoprotective effects, as assessed by [(3)H]thymidine uptake, (51)Cr release, and flow cytometry. In conclusion, our results reveal that disruption of homophilic interendothelial junctions induces VEGF expression. Under these conditions, autocrine VEGF appears to have a relevant role in death inhibition and proliferation of endothelial cells.


Subject(s)
Cadherins/physiology , Endothelial Growth Factors/biosynthesis , Endothelium, Vascular/pathology , Endothelium, Vascular/physiology , Gap Junctions/physiology , Lymphokines/biosynthesis , Animals , Autocrine Communication , Cattle , Cell Death/physiology , Cell Division/physiology , Cells, Cultured , Endothelium, Vascular/ultrastructure , Immunohistochemistry , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
8.
Acta Derm Venereol ; 79(6): 422-5, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10598753

ABSTRACT

The expression of vascular endothelial growth factor (VEGF) was analysed in biopsy samples from patients with pyogenic granuloma. The results disclosed the presence of a strong VEGF signal in pyogenic granulomas, which are constituted by a vast majority of cells of endothelial lineage. A marked positivity was evident in areas of proliferating endothelial cells without vessel lumen formation. In the same respect, staining for VEGF was less marked in the vessels with a well-developed lumen. The fact that VEGF production appears to be limited to endothelial cell precursors or immature endothelial cells prior to the complete development of the vessels, leads to the possibility that VEGF may act as an autocrine factor in circumstances of endothelial cell stimulation.


Subject(s)
Endothelial Growth Factors/analysis , Granuloma, Pyogenic/pathology , Lymphokines/analysis , Skin Diseases/pathology , Adolescent , Adult , Biomarkers/analysis , Biopsy, Needle , Female , Humans , Immunohistochemistry , Male , Middle Aged , Prognosis , Sensitivity and Specificity , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
9.
Arch Pediatr Adolesc Med ; 152(11): 1095-9, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9811287

ABSTRACT

OBJECTIVES: To determine the rate of occurrence of Gardnerella vaginalis in the genital tract and rectum of the asymptomatic prepubertal boy and to examine the effect of circumcision on the rate of recovery. DESIGN: A prospective survey design was used. Cultures for G vaginalis were obtained from the urethral meatus, surrounding glans, and rectum of prepubertal boys. Boys who had a history of sexual abuse, current urogenital symptoms, or who had taken antibiotics in the preceding 2 weeks were excluded from this study. SETTING: The study was conducted in ambulatory clinical settings at a children's hospital within a major medical center that serves as a statewide referral center. PARTICIPANTS: A group of 99 circumcised and uncircumcised prepubertal boys participated in the study. The participants ranged in age from 1 month to 7 years 4 months. MAIN OUTCOME MEASURE: Results of cultures for G vaginalis. RESULTS: No cultures were positive for G vaginalis from the urethra, glans, or rectum in any of the participants in this study. CONCLUSIONS: The findings of this study provide preliminary evidence that G vaginalis is not an organism that commonly colonizes the urogenital or gastrointestinal tract in asymptomatic prepubertal boys. Based on these findings, it does not seem prudent to apply the concept of asymptomatic colonization to prepubertal boys unless further studies refute these findings.


Subject(s)
Gardnerella vaginalis/isolation & purification , Genitalia, Male/microbiology , Rectum/microbiology , Case-Control Studies , Child , Child Abuse, Sexual , Child, Preschool , Circumcision, Male , Humans , Infant , Male , Prospective Studies , Sexually Transmitted Diseases, Bacterial/microbiology , Toilet Training
10.
J Am Soc Nephrol ; 9(11): 1998-2004, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9808085

ABSTRACT

The vascular actions of recombinant human erythropoietin (rhEPO) are of particular relevance for fully understanding rhEPO effects. This study examines the mechanisms of action of rhEPO on endothelial cells from bovine aorta (BAEC). First, the studies demonstrated that rhEPO acts on BAEC proliferation as a comitogenic growth factor in the presence of fetal calf serum (FCS). The main experimental findings disclosed that an interaction between rhEPO and vascular endothelial growth factor (VEGF) is instrumental for the growth-promoting action of rhEPO, as shown by the blockade (92.8+/-2.2% inhibition, P < 0.01) of the rhEPO-induced BAEC proliferation by a specific anti-VEGF antibody and by the capability of VEGF for substituting FCS in the induction of rhEPO-related BAEC proliferation (increase in BAEC number in the absence of FCS: 20 U/ml rhEPO alone, 0.3+/-2.8%; 5 x 10(-11) M VEGF alone, 52.9+/-3.1%; 20 U/ml rhEPO + 5 X 10(-11) M VEGF, 117.8+/-6.9%, P < 0.01 between the two agents combined with respect to each agent alone). The existence of a positive interaction between rhEPO and VEGF was further demonstrated by observing an increased cytosolic Ca2+ ([Ca2+]i) mobilization response to VEGF (10(-11)M) in BAEC pretreated or not with 20 U/ml rhEPO (delta[Ca2+]i = 704+/-111 versus 246+/-36 nM, respectively, P < 0.01). To further examine the mechanism of the potentiation of VEGF effect by rhEPO, we analyzed the mRNA expression of the VEGF receptors KDR/flk-1 and flt-1. The results disclosed that BAEC pretreatment with rhEPO upregulated the expression of both KDR/flk-1 and flt-1, therefore providing a structural basis for the aforementioned positive interactions between VEGF and rhEPO. Furthermore, inhibition by genistein suggests that tyrosine phosphorylation was involved in the VEGF receptor upregulation. The mechanisms identified in the present study disclose an interaction at the level of mRNA expression and functional effects between a hormone with predominantly hemopoietic effects, namely, erythropoietin, and an angiogenic factor, namely, VEGF. This relationship between rhEPO and VEGF might be of particular importance in neovascularization processes and in patients receiving rhEPO as a treatment.


Subject(s)
Endothelial Growth Factors/physiology , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Erythropoietin/pharmacology , Lymphokines/physiology , Animals , Aorta/cytology , Aorta/drug effects , Aorta/physiology , Cattle , Cell Division/drug effects , Cell Division/physiology , Endothelium, Vascular/physiology , Enzyme Inhibitors/pharmacology , Genistein/pharmacology , Humans , Protein-Tyrosine Kinases/antagonists & inhibitors , Proto-Oncogene Proteins/genetics , RNA, Messenger/metabolism , Receptor Protein-Tyrosine Kinases/genetics , Receptors, Growth Factor/genetics , Receptors, Vascular Endothelial Growth Factor , Recombinant Proteins , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factor Receptor-1 , Vascular Endothelial Growth Factors
11.
J Am Soc Nephrol ; 9(6): 969-74, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9621279

ABSTRACT

Angiotensin II (AngII) is a main mediator in the regulation of vascular tone. Although its effects on vascular smooth muscle cells are well known, data on its role on endothelial biology are still insufficient. The present study examined the effect of endogenous and exogenous AngII on bovine aortic endothelial cells possessing both AT-1 and AT-2 receptors. A DNA synthesis-promoting effect of AT-2 blockade by PD123319 (10(-9) to 10(-7) M) was demonstrated. This effect was transduced through an AT-1-mediated pathway, as shown by using the AT-1 antagonist, losartan. In addition, an AT-1-mediated effect of AngII was demonstrated on bovine aortic endothelial cell proliferation, which occurred despite the absence of AngII-induced Ca2+ transients. In summary, the present study disclosed relevant characteristics of the effect of AngII on endothelial cell growth that have potential pathophysiologic projections, particularly for the use of selective AngII blocking agents.


Subject(s)
Angiotensin II/pharmacology , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Receptors, Angiotensin/physiology , Angiotensin Receptor Antagonists , Animals , Calcium/metabolism , Cattle , Cell Count/drug effects , Cell Division/drug effects , Cell Line , DNA/biosynthesis , Dose-Response Relationship, Drug , Endothelium, Vascular/metabolism , Imidazoles/pharmacology , Losartan/pharmacology , Pyridines/pharmacology
12.
Nephrol Dial Transplant ; 13(3): 594-601, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9550633

ABSTRACT

BACKGROUND: The impaired renal function and vasodilatation that accompany age need to be re-addressed based upon the new knowledge concerning vascular nitric oxide (NO)-dependent systems. The present study examined the effects of age on the NO-related renal response. METHODS: The study was performed in euvolaemic, conscious Wistar rats, aged 5 and 18 months. Renal function and haemodynamic measurements with fluorescent microspheres were employed to assess differences between groups. RESULTS: A first set of experiments showed that ageing rats had a reduced natriuretic and diuretic response to acetylcholine, whereas the response to sodium nitroprusside was preserved. In the same regard, a reduction of the renal functional effects of L-arginine (L-Arg) and L-glycine (L-Gly) was found in the older rats. In the ageing rats, these responses were accompanied by an enhanced effect of the L-Arg competitive analogue, NwNLA, which provoked a marked reduction of renal function. This effect of NwNLA was blocked by the simultaneous administration of a small dose of L-Arg in the ageing but not in the young rats. Systemic haemodynamic studies revealed that in ageing rats, NwNLA reduced renal blood flow and increased renal vascular resistances in a significantly higher proportion than in younger animals. However, flow to other organs, namely, brain, spleen or liver, was affected in a similar manner in both young and old rats. Ultrastructural alterations were found in endothelial cells, which might constitute the anatomical basis for the observed functional derangements. CONCLUSIONS: The present experiments reveal that ageing is accompanied by significant differences in NO-related responses in the kidney which do not appear to affect blood flow to other organs. The response to L-Arg and L-Arg competitive analogues supports the existence of a marked dependency on NO-related mechanisms in the ageing rats, but not of a decreased baseline activity of the NO-dependent pathways.


Subject(s)
Aging/physiology , Kidney/physiology , Nitric Oxide/physiology , Acetylcholine/pharmacology , Animals , Antihypertensive Agents/pharmacology , Arginine/analogs & derivatives , Glomerular Filtration Rate , Hemodynamics , Kidney/blood supply , Kidney Function Tests , Male , Microspheres , Nitroprusside/pharmacology , Rats , Rats, Wistar
13.
J Bacteriol ; 177(24): 7131-40, 1995 Dec.
Article in English | MEDLINE | ID: mdl-8522520

ABSTRACT

The translation inhibitor microcin C7 (MccC7) is a linear heptapeptide whose N terminus has been replaced by an N-formyl group and whose C terminus has been replaced by the phosphodiester of 5'-adenylic acid and n-aminopropanol (J. I. Guijarro, J. E. González-Pastor, F. Baleux, J. L. San Millán, M. A. Castilla, M. Rico, F. Moreno, and M. Delepierre, J. Biol. Chem. 270:23520-23532, 1995). MccC7 production and immunity determinants lie on a 6.2-kb region of the Escherichia coli plasmid pMccC7. This region was entirely sequenced. It contains six open reading frames, which were shown to be true genes by different complementary approaches. Five genes, mccABCDE, which are transcribed in the same direction, are required to produce mature extracellular microcin. The sixth gene, mccF, adjacent to mccE, is transcribed in the opposite direction and encodes specific self-immunity. Genes mccA to -E constitute an operon transcribed from a promoter (mccp) located upstream of mccA. mccA is 21 nucleotides long and encodes the unmodified heptapeptide (J. E. González-Pastor, J. L. San Millán, and F. Moreno, Nature [London] 369:281, 1994). A comparison of predicted gene polypeptide products with those included in databases shows that an 81-amino-acid stretch of MccB is strikingly homologous to fragments of the same length of proteins ThiF and ChlN from E. coli, HesA from Anabaena sp. strain PCC7120, and UBA1, the ubiquitin-activating enzyme from different eukaryotic species. MccC displays several hydrophobic domains, suggesting a transmembrane location. The carboxyl end of MccE displays 41.2% identity with RimL, a protein required to acetylate the ribosome protein L12 from E. coli. In the absence of the other mcc genes, mccA impairs the growth of host cells, suggesting that unmodified MccA has antibiotic activity. A model for MccC7 biosynthesis, export, and immunity is proposed.


Subject(s)
Bacteriocins/genetics , Escherichia coli/genetics , Genes, Bacterial , Plasmids/genetics , Amino Acid Sequence , Bacteriocins/immunology , Base Sequence , Cloning, Molecular , Epitopes/genetics , Epitopes/immunology , Genetic Complementation Test , Molecular Sequence Data , Mutation , Protein Biosynthesis , Sequence Alignment , Sequence Analysis
14.
J Biol Chem ; 270(40): 23520-32, 1995 Oct 06.
Article in English | MEDLINE | ID: mdl-7559516

ABSTRACT

Escherichia coli microcin C7 (MccC7) is an antibiotic that inhibits protein synthesis in vivo. It is a heptapeptide containing unknown modifications at the N and C termini (García-Bustos, J. F., Pezzi, N., and Méndez, E. (1985) Antimicrob. Agents Chemoth. 27, 791-797). The chemical structure of MccC7 has been characterized by use of 1H homonuclear and heteronuclear (13C, 15N, 31P) nuclear magnetic resonance spectroscopy as well as mass spectrometry (1177 +/- 1 Da). The heptapeptide Met-Arg-Thr-Gly-Asn-Ala-Asp is substituted at the N terminus by a N-formyl group. The C-terminal substituent consists of the phosphodiester of 5'-adenylic acid and n-aminopropanol (AMPap), which is linked via the phosphorus atom to an amide group, thus forming a phosphoramide. The main chain carbonyl of the C-terminal aspartic acid residue is connected via this amide bond to the modified nucleotide unit. MccC7 and the peptide unit inhibit protein translation in vitro while a synthetic analog of the AMPap substituent is not active. Neither the peptide nor the AMPap molecule has an effect on the growth of MccC7-sensible cells. Our results strongly suggest that the peptide is responsible for MccC7 antibiotic activity while the C-terminal substituent is needed for MccC7 transport. Implications of the structure determined in this work for MccC7 synthesis and mode of action are discussed.


Subject(s)
Anti-Bacterial Agents/chemistry , Bacteriocins/chemistry , Amino Acid Sequence , Anti-Bacterial Agents/pharmacology , Bacteriocins/genetics , Bacteriocins/pharmacology , Escherichia coli/genetics , Mass Spectrometry , Molecular Sequence Data , Molecular Structure , Protein Biosynthesis , Protein Synthesis Inhibitors/chemistry , Protein Synthesis Inhibitors/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...